Overview

Y-3 for Injection in the Treatment of Acute Ischemic Stroke

Status:
RECRUITING
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This trial aims to evaluate the effectiveness and safety of Y-3 for injection in the treatment of patients with acute ischemic stroke within 48 hours of onset
Phase:
PHASE3
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborator:
Neurodawn Pharmaceutical Co., Ltd.
Treatments:
Injections